http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
서애리,이현숙,김영순 高麗大學校 倂設 保健大學 保健科學硏究所 2000 保健科學論集 Vol.26 No.1
Cognitive decline is perceived to be a characteristic of the aging process, and is profoundly manifested in age-related neurodegenerative disorders such as Aizheimer's Disease(AD). The pathologic mechanisms underlying neurodegeneration are complex and not completely understood, but a contributing factor is believed to be oxidative stress. The brain has a high metabolic requirement for oxygen and a high concentration of polyunsaturated fatty acids, and therefore is prone to lipid peroxidation. Lipid peroxidation leads to the production of free radicals that may attack and irreversibly damage neural tissue, thus contributing directly or synergistically to neurodegenerative process. Accumulating evidence from preclinical and clinical studies supports the hypothesis that oxidative stress may be associated with the onset and progression of AD. Antioxident therapies are being promoted in the lay press to enhance mental functions and delay cognitive losses with aging. This paper summarizes the oxidative stress hypothesis of AD and reviews the strengths and limitations of published antioxidant studies in AD in relation to the role of such therapies in practice.
숙명박물관 브랜드 프로모션을 위한 통합적 브랜드 개발 -2D, 3D, 4D 디자인 프로세스를 중심으로-
길혜경,김보현,오정은,이서연,이지원,이진민,장미정,이성애 숙명여자대학교 산업디자인연구소 2017 숙명디자인학 연구 Vol.24 No.-
본 연구는 여성생활사 중심의 유물 박물관인 숙명박물관의 인지도와 브랜딩의 문제를 해결하기 위해 브랜드·스페이스·마케팅을 활용한 통합 브랜드 개발 프로세스를 제안하는데 목적이 있다. 아울러 본 연구는 박물관의 브랜드를 프로모션하고 그래픽, 제품, 공간의 통합 브랜드를 구축하는 일련의 프로세스를 밝히는데 목적이 있다. 이에 본 연구의 시간적 범위는 2017년 3월부터 6월까지 총 15주간 숙명여대 환경디자인학과 <브랜드·스페이스·마케팅>수업에서 진행된 수업의 결과물로서 4개 팀 중, 1개 팀의 작업물로 한다. 본 연구의 대상적 범위는 ‘숙명여자대학교 숙명박물관'의 2D~4D까지의 전반으로 설정한다. 그 결과, 제품부터 공간까지 숙명박물관의 통합된 브랜딩은 일 관성과 객관성, 스토리성을 얻을 수 있었다. ’숙명박물관'은 학교의 박물관이라는 장점을 극대화시켜 가치와 스토리를 부여하고 하나의 브랜드로 리뉴얼했다는 점에서 의의가 있다. 또한 향후 보편적인 박물관들의 차별화된 브랜드 개발의 참고자료로 활용될 수 있을 것으로 기대하며 브랜드 개발에 있어서 G·I, P·I, S·I의 통합 브랜드 메뉴의 기초 자료로 활용될 것으로 사료된다.
Torsion of corpus luteum cyst in the second trimester of normal pregnancy : A case report
( Hyun Kyoung Seo ),( Seon Mi Lee ),( Jae Yoon Jo ),( Hee Jung Lee ),( Yeon Jee Lee ),( In Ae Cho ),( Jeong Kyu Shin ),( Won Jun Choi ),( Jong Hak Lee ),( Won Young Paik ),( Soon Ae Lee ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Torsion of corpus luteum cyst is rare case of gynecologic surgical emergency during pregnancy. The patient of adnexa torsion complain non-specific symptom such as abdominal pain, palpable mass, nausea, vomiting, and abdominal distension. So. It makes the differential diagnosis difficulty. Ovarian torsion cause venous and lymphatic compression and hemorrhagic ischemia, lead to ovarian stroma necrosis. Early detection and treatment is crucial to maintain pregnancy and preserve fertility. We report here a case of 32-year old women with 17+2 weeks of pregnancy with left lower abdominal pain. And she complain nausea and vomiting. The patient was diagnosed with a left ovarian torsion, and we performed surgical treatment. After surgery, we confirmed that the fetal heart tone was normal. If ovarian torsion is left untreatened, it may cause problems in fetal well-being and complications such as peritonitis. Therefore, a reasonable discrimination by the surgeon is essential when the patient with acute abdominal pain during pregnancy. Transabdominal sonography, including color Doppler can help with the diagnosis of ovarian torsion. MRI also help diagnose this disease without the risk of fetal radiation exposure. In general, treatment of ovarian torsion is laparoscopic surgery, but treatment of adnexa torsion during pregnancy should be assessed by gestational age and the fetal condition.
Seo, In-Ae,Lee, Hyun-Kyoung,Shin, Yoon-Kyung,Lee, Sang-Hwa,Seo, Su-Yeong,Park, Ji-Wook,Park, Hwan-Tae The Korean Society of Pharmacology 2009 The Korean Journal of Physiology & Pharmacology Vol.13 No.2
The binding of interleukin-6 (IL-6) cytokine family ligands to the gp130 receptor complex activates the Janus kinase (JAK)/ signal transducer and activator of transcription 3 (STAT3) signal transduction pathway, where STA T3 plays an important role in cell survival and tumorigenesis. Constitutive activation of STAT3 has been frequently observed in many cancer tissues, and thus, blocking of the gp130 signaling pathway, at the JAK level, might be a useful therapeutic approach for the suppression of STAT3 activity, as anticancer therapy. AG490 is a tyrphostin tyrosine kinase inhibitor that has been extensively used for inhibiting JAK2 in vitro and in vivo. In this study, we demonstrate a novel mechanism associated with AG490 that inhibits the JAK/STAT3 pathway. AG490 induced downregulation of gp130, a common receptor for the IL-6 cytokine family compounds, but not JAK2 or STAT3, within three hours of exposure. The downregulation of gp130 was not caused by enhanced degradation of gp130 or by inhibition of mRNA transcription. It most likely occurred by translation inhibition of gp130 in association with phosphorylation of the eukaryotic initiation factor-2 a. The inhibition of protein synthesis of gp130 by AG490 led to immediate loss of mature gp130 in cell membranes, due to its short half-life, thereby resulting in reduction in the STAT3 response to IL-6. Taken together, these results suggest that AG490 blocks the STAT3 activation pathway via a novel pathway.
The Role of Nrf2: Adipocyte Differentiation, Obesity, and Insulin Resistance
Seo, Hyun-Ae,Lee, In-Kyu Hindawi Publishing Corporation 2013 Oxidative medicine and cellular longevity Vol.2013 No.-
<P>Metabolic diseases, such as type 2 diabetes and obesity, are increasing globally, and much work has been performed to elucidate the regulatory mechanisms of these diseases. Nuclear factor E2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor that serves as a primary cellular defense against the cytotoxic effects of oxidative stress. Recent studies have proposed a close relationship between oxidative stress and energy metabolism-associated disease. The Nrf2 pathway, as a master regulator of cellular defense against oxidative stress, has emerged as a critical target of energy metabolism; however, its effects are controversial. This review examines the current state of research on the role of Nrf2 on energy metabolism, specifically with respect to its participation in adipocyte differentiation, obesity, and insulin resistance, and discusses the possibility of using Nrf2 as a therapeutic target in the clinic.</P>
In Ae Seo,Hyun Kyoung Lee,Yoon Kyung Shin,Sang Hwa Lee,Su-Yeong Seo,Ji Wook Park,Hwan Tae Park 대한생리학회-대한약리학회 2009 The Korean Journal of Physiology & Pharmacology Vol.13 No.2
The binding of interleukin-6 (IL-6) cytokine family ligands to the gp130 receptor complex activates the Janus kinase (JAK)/ signal transducer and activator of transcription 3 (STAT3) signal transduction pathway, where STAT3 plays an important role in cell survival and tumorigenesis. Constitutive activation of STAT3 has been frequently observed in many cancer tissues, and thus, blocking of the gp130 signaling pathway, at the JAK level, might be a useful therapeutic approach for the suppression of STAT3 activity, as anticancer therapy. AG490 is a tyrphostin tyrosine kinase inhibitor that has been extensively used for inhibiting JAK2 <i>in vitro</i> and <i>in vivo</i>. In this study, we demonstrate a novel mechanism associated with AG490 that inhibits the JAK/STAT3 pathway. AG490 induced downregu</I>lation of gp130, a common receptor for the IL-6 cytokine family compounds, but not JAK2 or STAT3, within three hours of exposure. The downregulation of gp130 was not caused by enhanced degradation of gp130 or by inhibition of mRNA transcription. It most likely occurred by translation inhibition of gp130 in association with phosphorylation of the eukaryotic initiation factor-2Ձ. The inhibition of protein synthesis of gp130 by AG490 led to immediate loss of mature gp130 in cell membranes, due to its short half-life, thereby resulting in reduction in the STAT3 response to IL-6. Taken together, these results suggest that AG490 blocks the STAT3 activation pathway via a novel pathway.